Curie: The Oncology Brief

Curie: The Platform for HCPs
  • 0.0 (0)
  • MEDICINE

Catch up quickly with The OncoBrief, your weekly digest of the top three oncology stories that matter most. Delivered clearly and concisely, we cover clinical breakthroughs, FDA approvals, and emerging trends keeping oncologists informed and ahead.

  1. Radiation Oncology Consolidation, Neuropathy Prevention, and New Immunotherapy for HCC

    03/21/2025

    Radiation Oncology Consolidation, Neuropathy Prevention, and New Immunotherapy for HCC

    Love what you hear? Download the Curie app from the App Store today. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three key updates in oncology. A new analysis shows that radiation oncology practices are consolidating rapidly, raising concerns about access to care, patient choice, and job stability for oncologists. In breast cancer, a randomized trial finds that hand cooling and compression can significantly reduce chemotherapy-induced neuropathy, offering a simple, cost-effective strategy to protect patients’ nerves. And finally, the EMA has recommended expanding nivolumab plus ipilimumab for advanced hepatocellular carcinoma, positioning it as an alternative to the current standard of care. Tune in for the latest insights shaping cancer treatment.

    6 min
  2. MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate

    03/21/2025

    MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate

    Love what you hear? Download the Curie app from the App Store today. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRD’s growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain FDA approval—what does this mean for patients enrolling in these studies? Finally, we examine the rapid expansion of Hospital-at-Home care, a model that could change oncology treatment, but also raises concerns about patient safety and healthcare equity. Tune in for the latest updates and insights.

    6 min
  3. Datopotamab Deruxtecan Approved, Immunotherapy Timing, and Rising Early-Onset Colorectal Cancer

    03/21/2025

    Datopotamab Deruxtecan Approved, Immunotherapy Timing, and Rising Early-Onset Colorectal Cancer

    In this episode of Curie, Matt covers three major developments in oncology. The FDA has approved datopotamab deruxtecan (Datroway) for HR positive, HER2 negative breast cancer, marking a new era for antibody-drug conjugates in this disease. A meta-analysis suggests that the timing of immunotherapy infusions may impact survival outcomes, raising questions about how circadian rhythms influence treatment response. Finally, a global analysis confirms that early-onset colorectal cancer is on the rise worldwide, challenging current screening guidelines and prompting discussions on prevention strategies. Tune in for the latest insights shaping cancer care.

    6 min
  4. ASCO Ovarian Cancer Guidelines, Mammo-50 Breast Cancer Surveillance, and NRG1 Fusion Therapy Advances

    03/21/2025

    ASCO Ovarian Cancer Guidelines, Mammo-50 Breast Cancer Surveillance, and NRG1 Fusion Therapy Advances

    In this episode of Curie, Matt breaks down three major updates in oncology. ASCO has released updated guidelines for advanced ovarian cancer, emphasizing primary cytoreductive surgery over neoadjuvant chemotherapy when feasible. The Mammo-50 trial challenges the standard of annual mammographic surveillance for breast cancer survivors over 50, showing that less frequent screening is non-inferior. Finally, the eNRGy trial confirms the efficacy of zenocutuzumab in treating NRG1 fusion-positive cancers, a rare but actionable oncogenic driver in NSCLC and pancreatic cancer. Tune in for expert insights into how these findings are shaping cancer care.

    7 min
  5. New Approvals in Oncology: Vimseltinib for TGCT, Sotorasib for KRAS G12C CRC, and Immunotherapy in ER Positive Breast Cancer

    03/21/2025

    New Approvals in Oncology: Vimseltinib for TGCT, Sotorasib for KRAS G12C CRC, and Immunotherapy in ER Positive Breast Cancer

    Love what you hear? Download the Curie app from the App Store today. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three major updates in oncology. Vimseltinib (Romvimza) has been FDA-approved for tenosynovial giant cell tumors (TGCT), providing a new non-surgical option for symptomatic patients. Sotorasib plus panitumumab is now approved for KRAS G12C-mutated colorectal cancer, marking a breakthrough in targeted therapy for this hard-to-treat population. Finally, two phase III trials show that adding immunotherapy to neoadjuvant chemotherapy improves pathological complete response rates in high risk ER positive, HER2 negative breast cancer—a potential paradigm shift in treatment. Tune in for the latest updates in precision oncology!

    6 min
  6. PSA Screening Debate, Brain Metastases in HER2 Positive Breast Cancer, and Subcutaneous Immunotherapy

    03/21/2025

    PSA Screening Debate, Brain Metastases in HER2 Positive Breast Cancer, and Subcutaneous Immunotherapy

    Love what you hear? Download the Curie app from the App Store today. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt breaks down three critical updates in oncology. A new study links declining PSA screening rates to a rise in advanced prostate cancer cases, raising questions about early detection guidelines. We then explore new findings on brain metastases in HER2 positive breast cancer, revealing how patients with CNS only disease have significantly better outcomes than those with extracranial spread. Finally, the FDA has approved subcutaneous nivolumab, offering a faster, more convenient immunotherapy option for multiple cancers. Tune in for the latest insights shaping cancer care!

    5 min
  7. Next-Gen Cancer Treatments: HER2-Mutated Breast Cancer, NSCLC ADCs, and FGFR Resistance

    03/21/2025

    Next-Gen Cancer Treatments: HER2-Mutated Breast Cancer, NSCLC ADCs, and FGFR Resistance

    Love what you hear? Download the Curie app from the App Store today. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt explores game-changing developments in oncology. Learn about the latest chemotherapy-free approach for HER2-mutated metastatic breast cancer, where tucatinib and trastuzumab are showing durable responses. Discover how datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, is offering new hope for EGFR-mutated and ALK-rearranged NSCLC patients. Finally, dive into groundbreaking insights on FGFR inhibitor resistance in cholangiocarcinoma—and how liquid biopsies could revolutionize treatment strategies. Stay informed and ahead of the curve with these cutting-edge updates in precision oncology!

    5 min
  8. ASCO GI 2025 Highlights: Transforming Gastrointestinal Cancer Care

    03/21/2025

    ASCO GI 2025 Highlights: Transforming Gastrointestinal Cancer Care

    Love what you hear? Download the Curie app from the App Store today. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. From nivolumab-plus-ipilimumab in colorectal cancer to the latest CAR-T therapies in GI malignancies, explore the cutting-edge breakthroughs from ASCO GI 2025. This episode covers transformative data that’s reshaping the future of GI oncology.

    5 min
See All (20)

About

Catch up quickly with The OncoBrief, your weekly digest of the top three oncology stories that matter most. Delivered clearly and concisely, we cover clinical breakthroughs, FDA approvals, and emerging trends keeping oncologists informed and ahead.

Information